MML Investors Services
AVDL

MML Investors Services’s Avadel Pharmaceuticals AVDL Stock Holding History

MML Investors Services’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-217,573
Closed -$4.69M – 3006
2025
Q4 		$4.69M Sell
217,573
-9,820
-4% -$191K 0.01% 904
2025
Q3 		$3.47M Buy
227,393
+20,015
+10% +$260K 0.01% 1019
2025
Q2 		$1.83M Buy
207,378
+13,072
+7% +$115K 0.01% 1297
2025
Q1 		$1.52M Buy
194,306
+27,000
+16% +$226K 0.01% 1335
2024
Q4 		$1.76M Buy
167,306
+30,950
+23% +$376K 0.01% 1188
2024
Q3 		$1.79M Buy
136,356
+16,500
+14% +$251K 0.01% 1152
2024
Q2 		$1.69M Buy
119,856
+17,925
+18% +$292K 0.01% 1119
2024
Q1 		$1.72M Buy
101,931
+27,050
+36% +$403K 0.01% 1116
2023
Q4 		$1.06M Buy
74,881
+2,294
+3% +$26.9K ﹤0.01% 1325
2023
Q3 		$748K Buy
72,587
+21,987
+43% +$294K ﹤0.01% 1398
2023
Q2 		$834K Buy
50,600
+15,500
+44% +$201K ﹤0.01% 1325
2023
Q1 		$322K Buy
35,100
+1,000
+3% +$8.22K ﹤0.01% 1638
2022
Q4 		$244K Buy
34,100
+1,000
+3% +$7.01K ﹤0.01% 1904
2022
Q3 		$166K Hold
33,100
– – ﹤0.01% 1968
2022
Q2 		$81K Buy
33,100
+5,100
+18% +$20.9K ﹤0.01% 1986
2022
Q1 		$191K Buy
+28,000
New +$192K ﹤0.01% 1979

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

MML Investors Services's AVDL Position: Q1 2026 in Review

MML Investors Services sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 217,573 shares — an estimated $4.69M sold.

MML Investors Services first reported a position in AVDL in Q1 2022 and held it in 16 quarters. The position peaked at $4.69M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • MML Investors Services reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • MML Investors Services sold 217,573 Avadel Pharmaceuticals shares in Q1 2026, an estimated $4.69M.
  • MML Investors Services first reported a position in Avadel Pharmaceuticals in Q1 2022 and held it in 16 quarters.
  • MML Investors Services's Avadel Pharmaceuticals position peaked at $4.69M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on MML Investors Services's 13F filing for Q1 2026, filed 4 May 2026.